PD-L1
PD-L1, also known as CD274 or B7-H1, is an immune-checkpoint protein that participates in the PD-1/PD-L1 regulatory axis.
PD-L1, also known as CD274 or B7-H1, is an immune-checkpoint protein that participates in the PD-1/PD-L1 regulatory axis. In cancer, PD-L1 expression is investigated as a mechanism of immune evasion and as a therapeutic biomarker. Its interaction with the PD-1 pathway can suppress antitumor T-lymphocyte activity; in particular, increased PD-L1 expression has been associated with impaired CD8-positive T-cell-mediated cytotoxicity in experimental gastric cancer models 42217559May.
PD-L1 is therefore a major target of cancer immunotherapy and checkpoint inhibitor development. Current approaches represented in the cited literature include antibody blockade, engineered microbial delivery of a PD-L1-blocking nanobody, small molecules that bind PD-L1, combinations with chemotherapy or radiotherapy, and imaging agents intended to measure PD-L1 expression. The recent work also emphasizes that PD-L1 expression may vary across tumor types, anatomical compartments, metastatic sites, and treatment contexts.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
11 papers study pd-l1 directly. The themes below are drawn from those 11. 1 paradigm shift follows.
-
Tumor-Targeted Immunotherapy : Combination and tumor-targeted approaches are expanding beyond antibody blockade: gemcitabine-associated lactylation, engineered probiotics, macrophage-directed mRNA nanoparticles and small-molecule PD-1/PD-L1 modulators aim to improve responses, while radiotracers map expression. 5 papers · 45.5%
-
Tumor Immune Evasion Signaling : Mechanistic work links oncogenic signaling to PD-L1-mediated immune escape through AR/ARD1/DLGAP5 and circFXR1-mTOR pathways. Direct small-molecule radiosensitization and CD73/PD-L1 profiling extend this focus toward actionable immune-evasion biology across tumors. 4 papers · 36.4%
-
Head and Neck Cancer Biomarkers : The focus is shifting from single PD-L1 scores toward spatial and systemic immune profiling in head and neck squamous cancers. c-MET heterogeneity, CPS and immune correlates are being related to response to pembrolizumab plus chemoradiotherapy after resection. 2 papers · 18.2%
PD-L1 is a spatially and biologically contextual marker rather than a uniform predictor of treatment response
The oral squamous cell carcinoma study of matched primary tumors and lymph-node metastases 42747499Sep and the adjuvant pembrolizumab–chemoradiotherapy study in high-risk head and neck squamous cell carcinoma 42347893Jun both challenge the assumption that a single PD-L1 measurement represents tumor immune status consistently across a patient. PD-L1 differed between primary and metastatic compartments in the oral cancer cohort, while in the head and neck trial a high overall PD-L1 combined positive score was associated with numerically worse disease-free survival even as greater densities of PD-L1-positive stromal cells were associated with better outcomes. PD-L1 interpretation therefore shifts from a uniform biomarker model to one requiring anatomical compartment and cellular context.
Recent Findings on PD-L1
Oncogenic regulation and immune evasion: In androgen receptor-positive triple-negative breast cancer, the AR/ARD1/DLGAP5 axis was investigated as a driver of oncogenesis and immune evasion through PD-L1 upregulation. This study extends the theme of PD-L1-mediated immune evasion by linking checkpoint expression to a defined androgen receptor-associated molecular program 42749183Sep.
In gastric cancer, exosomal circFXR1 was reported to promote tumor progression and immune evasion through coordinated regulation of PD-L1 and mTOR signaling. Mechanistically, circFXR1 interacted with miR-497-5p, leading to increased PD-L1 expression and reduced CD8-positive T-cell cytotoxicity 42217559May.
A study of meningiomas evaluated CD274/PD-L1 together with CD39/ENTPD1, CD73/NT5E, and systemic inflammatory features in patients undergoing surgical resection of WHO grade 1 and grade 2 tumors. The work placed PD-L1 within a broader purinergic and immune-related profile, although the supplied publication context does not report specific associations with clinical outcomes 42736467Sep.
Spatial and disease-specific expression: In oral squamous cell carcinoma, investigators examined PD-L1 and c-MET expression in matched primary tumors and lymph-node metastases. The study specifically addressed potential compartment-specific differences between primary and metastatic lesions, extending investigation of PD-L1 heterogeneity in squamous carcinoma 42747499Sep.
In high-risk head and neck squamous cell carcinoma treated with concurrent pembrolizumab and chemoradiotherapy, researchers assessed tumoral and systemic immune correlates of response. The rationale was that chemoradiotherapy may upregulate PD-1/PD-L1 immune checkpoints and that pembrolizumab could help reverse treatment-associated immunosuppression 42347893Jun.
Combination immunotherapy and targeted delivery: Engineered Escherichia coli Nissle 1917 was used as a tumor-targeted platform for combination chemoimmunotherapy. The bacteria expressed cytosine deaminase, which converts 5-fluorocytosine into 5-fluorouracil, while simultaneously producing an IL-15 superagonist and a PD-L1-blocking nanobody within tumors 42748218Sep.
In a study targeting tumor-associated macrophages with mRNA lipid nanoparticles, combining the nanoparticle strategy with checkpoint inhibitors against PD-L1 and CTLA-4 promoted a CTL-favoring immune environment and durable memory immunity in the reported experimental system 42726873Sep.
Chemotherapy-associated modulation: In colorectal cancer, gemcitabine was investigated as a sensitizer to anti-PD-L1 therapy. The study reported that gemcitabine delayed PD-L1 protein degradation, as confirmed by cycloheximide-treatment experiments, providing a proposed molecular basis for enhanced sensitivity to anti-PD-L1 treatment 42322856Jun.
Small-molecule targeting and radiosensitization: New thiazole-biaryl small-molecule immunomodulators were evaluated against the PD-1/PD-L1 axis. Isothermal titration calorimetry confirmed direct binding of both reported compounds to PD-L1; compound 17h showed stronger binding than 17t, with reported dissociation constants of 1.43 μM and 19.8 μM, respectively 42162747May.
Another study evaluated PD-L1-targeted small molecules in non-small-cell lung cancer, focusing on both direct antitumor activity and radiosensitization. This work broadens PD-L1 targeting beyond antibody checkpoint blockade toward compounds intended to influence tumor response to radiation 42447749Jul.
Imaging and treatment monitoring: A preclinical study evaluated the radiotracer [^68Ga]Ga-MRCP for imaging PD-L1 expression in colorectal cancer. The investigators reported that the tracer specifically targeted PD-L1 and proposed its use for dynamic monitoring of PD-L1 expression during immunotherapy 42364379Jun.
Taken together, these publications extend the principal literature themes of PD-L1-targeted cancer immunotherapy, PD-L1-mediated immune evasion, and PD-L1 investigation in squamous carcinoma. They place PD-L1 within combination strategies involving chemotherapy, radiotherapy, CTLA-4 blockade, IL-15 stimulation, tumor-targeted bacteria, mRNA nanoparticles, and molecular imaging, while also highlighting the importance of PD-L1 expression patterns across tumors and metastatic compartments.
Written from 11 PubMed abstracts, each one cited by PMID above. Published: 2026-09-18. Drafted by language models from published abstracts; not medical advice.